Drug intelligence / Profile preview

GEN1055 + pembrolizumab

Development stage: Unknown
Lead developer: BioNTech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GEN1055 + pembrolizumab is a combination therapy under investigation for advanced solid tumors. GEN1055 is a novel antibody developed to enhance immune-mediated tumor elimination, and pembrolizumab is a monoclonal antibody targeting the programmed death-1 (PD-1) receptor on T cells, acting as a checkpoint inhibitor. The combination aims to leverage GEN1055’s immune-activating mechanism with pembrolizumab’s blockade of the PD-1 pathway to improve antitumor responses in patients with advanced or metastatic cancers[1][2][3][4].

Brand names: pembrolizumab (Keytruda)
Other names: GEN1055 + pembrolizumab

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on GEN1055 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN1055 + pembrolizumab.

Explore the full profile